Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate

Annals of Clinical and Laboratory Science

Volumn 37, Issue 2, 2007, Pages 158-166

  Wu, Ta Jen ^a   Ou, Horng Yih ^a   Chou, Chien Wen ^b   Hsiao, Shu Hwa ^a   Lin, Chia Yin ^a   Kao, Pai C ^c  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c MAYO CLINIC   (United States)

Author keywords

Diabetes mellitus; Erythrocyte sedimentation rate; Fenofibrate; Fibrinogen; hs CRP; Proinsulin

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; FENOFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROINSULIN; TRIACYLGLYCEROL; URIC ACID;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; ERYTHROCYTE SEDIMENTATION RATE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FIBRINOGEN; HUMANS; HYPERLIPIDEMIAS; OUTPATIENTS; PROCETOFEN; PROINSULIN; RISK FACTORS; TRIGLYCERIDES;

EID: 34248187694     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003;26(Suppl 1):83-86.
2. Kirchgässler KU, Schmitz H, Bach G. Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia. Clin Drug Invest 1998;15:197-204.
3. Jen SL, Chen JW, Lee WL, Wang SP. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type lib hyperlipidemia: a single-blind, randomized, and cross-over study. Zhonghua Yi Xue Za Zhi (Taipei) 1997;59:217-224.
4. Balfour JA, McTavish D, Heel RC. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990;40:260-290.
5. Corti R, Osende J, Hutter R, Viles-Gonzalez JF, Zafar U, Valdivieso C, Mizsei G, Fallon JT, Fuster V, Badimon JJ. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis 2006 Apr 4. Epub ahead of print.
6. Anon. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-910.
7. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001;3:83-92.
8. Silvestri E, de Lange P, Moreno M, Lombardi A, Ragni M, Feola A, Schiavo L, Goglia F, Lanni A. Fenofibrate activates the biochemical pathways and the de novo expression of genes related to lipid handling and uncoupling protein-3 functions in liver of normal rats. Biochim Biophys Acta 2006;1757:486-495.
9. Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother 2004;38:110-118.
10. Ingelsson E, Arnlov J, Sundstrom J, Lind L. Inflammation, as measured by the erythrocyte sedimentation rate, is an independent predictor for the development of heart failure. J Am Coll Cardiol 2005;45:1802-1806.
11. Godsland IF, Bruce R, Jeffs JA, Leyva F, Walton C, Stevenson JC. Inflammation markers and erythrocyte sedimentation rate but not metabolic syndrome factor score predict coronary heart disease in high socioeconomic class males: the HDDRISC study. Int J Cardiol 2004;97:543-550.
12. Kao PC, Shiesh SC, Wu TJ. Serum C-reactive protein as a marker for wellness assessment. Ann Clin Lab Sci 2006;36:163-169.
13. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Pagano G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;125:653-657.
14. Wu TJ, Lin CL, Taylor RL, Kao PC. Proinsulin level in diabetes mellitus measured by a new immunochemiluminometric assay. Ann Clin Lab Sci 1995;25:467-474.
15. Lindahl B, Dinesen B, Eliasson M, Roder M, Jansson JH, Huhtasaari F, Hallmans G. High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population. Metabolism 1999;48:1197-1202.
16. Alssema M, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ, Hoorn Study. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care 2005;28:860-865.
17. Langenfeld MR, Forst T, Standl E, Strotmann HJ, Lubben G, Pahler S, Kann P, Pfutzner A, IRIS II Study. IRIS II Study: sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. Diabetes Technol Ther 2004;6:836-843.
18. Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH, Lee KU. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 2003;52:2331-2337.
19. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000;275:16638-16642.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
21. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000;133:81-91.
22. Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, Kim NH, Choi DS, Baik SH. Comparison of serum concentrations of C-reactive protein, TNF-alpha, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract 2004;64:99-106.
23. Schillinger M, Exner M, Amighi J, Mlekusch W, Sabeti S, Rumpold H, Wagner O, Minar E. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation 2003;108:2323-2328.
24. Coban E, Ozdogan M, Yazicioglu G, Sari R. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients. Int J Clin Pract 2005;59:415-418.
25. Coban E, Sari R. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients. Endocr Res 2004;30:343-349.
26. Sebestjen M, Keber I, Zegura B, Simcic S, Bozic M, Fressart MM, Stegnar M. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost 2004;92:1129-1135.
27. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men: a nuclear magnetic resonance study. J Atheroscler Thromb 2004;11:278-285.
28. Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, Poledne R, Stavek P, Ceska R. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002;144:E6.
29. Tsimihodimos V, Kostoula A, Kakafika A, Bairaktari E, Tselepis AD, Mikhailidis DP, Elisaf M. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004;9:27-33.
30. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T. Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004;103;4188-4194.
31. Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem 2004;279:16154-16160.
32. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-2534.
33. Han KH, Hong KH, Park JH, Ko J, Kang DH, Choi KJ, Hong MK, Park SW, Park SJ. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004;109:2566-2671.
34. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC, European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. NEJM 1995;332:635-641.
35. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. NEJM 1999;340:448-454. Erratum in: NEJM 1999;340:1376.
36. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003;92:10i-18i.
37. Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006;91:1770-1778.
38. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005;28:1419-1424.
39. Kon Koh K, Yeal Ahn J, Hwan Han S, Kyu Jin D, Sik Kim H, Cheon Lee K, Kyun Shin E, Sakuma I. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaquestabilization, and hemostasis. Atherosclerosis 2004;174:379-383.
40. Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metabolism 2005;54:677-681.
41. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res 2001;52:290-298.
42. Avogaro A, Beltramello P, Marin R, Zambon S, Bonanome A, Biffanti S, Confortin L, Manzato E, Crepaldi G, Tiengo A. Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients. Atherosclerosis 1995;113:117-124.
43. Jeng CY, Sheu WH, Fuh MM, Shieh SM, Chen YD, Reaven GM. Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. J Clin Endocrinol Metab 1996;81:2550-2553.
44. Sane T, Knudsen P, Vuorinen-Markkola H, Yki-Jarvinen H, Taskinen MR. Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. Metabolism 1995;44:589-596.
45. Pfutzner A, Kann PH, Pfutzner AH, Kunt T, Larbig M, Weber MM, Forst T. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance. Clin Lab 2004;50:567-573.
46. Haffner SM, D'Agostino R, Mykkanen L, Hales CN, Savage PJ, Bergman RN, O'Leary D, Rewers M, Selby J, Tracy R, Saad MF. Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study. Stroke 1998;29:1498-1503.
47. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laasko M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial. Lancet 2005;366:1849-1861.
48. Wierzbicki AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006;60:442-449.
49. Cicero AF, Derosa G, Miconi A, Laghi L, Nascetti S, Gaddi A. Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10? Biofactors 2005;23:7-14.
50. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006;166:737-741.